{"title":"Human vaccines & immunotherapeutics: News July 2023.","authors":"Ronald Ellis, Adam Weiss","doi":"10.1080/21645515.2023.2244848","DOIUrl":null,"url":null,"abstract":"The anti-Clever-1 MAb bexmarilimab (Faron Pharma) combined with chemotherapy induced >50% objective response rate in 15 patients with myelodysplastic syndromes and relapsed or refractory acute myeloid leukemia. The Phase 1/2 BEXMAB trial also investigated safety and tolerability at several dosage levels. Bexmarilimab targets the macrophage surface protein Clever-1, whose activity leads to immune suppression and tumor growth. By interfering with its function, bexmarilimab induces M2-to-M1 macrophage switch and sensitization to chemotherapy.","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 2","pages":"2244848"},"PeriodicalIF":4.8000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c2/ad/KHVI_19_2244848.PMC10408690.pdf","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21645515.2023.2244848","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10
Abstract
The anti-Clever-1 MAb bexmarilimab (Faron Pharma) combined with chemotherapy induced >50% objective response rate in 15 patients with myelodysplastic syndromes and relapsed or refractory acute myeloid leukemia. The Phase 1/2 BEXMAB trial also investigated safety and tolerability at several dosage levels. Bexmarilimab targets the macrophage surface protein Clever-1, whose activity leads to immune suppression and tumor growth. By interfering with its function, bexmarilimab induces M2-to-M1 macrophage switch and sensitization to chemotherapy.
期刊介绍：
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
